ELV — Elevance Health Inc. stock price and chart

ELV

Elevance Health Inc.Stock · HealthcareS&P 500 Equal Weight 0.2% · S&P 500 0.1% · Russell 1000 0.1% · Russell 3000 0.1% · US Stock Market 0.1% · MSCI World 0.10% · MSCI ACWI 0.08%

$418.72+0.52%

as of market close, Sep 11, 2026

☾ AH — —

PeersMRNALLYUNHJNJMRKABBV

Technical analysis2

Overlay lines0

Addendum charts0

VolumeDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD

20162019202120242026

150.0200.0250.0300.0350.0400.0450.0500.0550.0010.0M20.0M$418.72

2026-09-11

Price$418.72

MA20$381.49

MA50$347.72

Vol8.0M

What would $1,000 invested in ELV be worth today? →

ELV returns: By year · By month · By week · Trailing

Key stats

Price data

Price: $418.72
Change YTD: +20.67%
Next earnings: Oct 20, 2026
Market cap: 90.8B2016-09 33B2026-09 90.8B+175.2% over the window
Enterprise value: 112.4B
Shares outstanding: 216.9M2016-06 263.2M2026-06 216.9M-17.6% over the window
52W low: $274.84
52W high: $436.24
From 52W high: -4.02%
From 52W low: +52.35%
52W range: 89%
Beta: 0.68

Volume

Rel volume: 1.34×
30D volume: 992.1K
30D $ vol: 395.4M

Fundamentals

Sales (ttm): 201.1B2016-06 81.8B2026-06 201.1B+145.8% over the window
Sales/share: $927.352016-06 $310.972026-06 $927.35+198.2% over the window
EPS (ttm): $22.472016-06 $8.652026-06 $22.47+159.7% over the window
FCF (ttm): 6.3B2016-06 2.8B2026-06 6.3B+128.0% over the window
FCF/share: $29.002016-06 $10.482026-06 $29.00+176.7% over the window
Book value/share: $206.962016-06 $92.092026-06 $206.96+124.7% over the window
Net margin: 2.47%2016-06 2.8%2026-06 2.5%-12.9% over the window
ROE: 11.06%2016-06 9.6%2026-06 11.1%+15.5% over the window
ROA: 3.93%2016-06 3.6%2026-06 3.9%+8.4% over the window
Debt / equity: 0.68×2016-06 0.592026-06 0.68+16.6% over the window
Current ratio: 1.522016-06 1.582026-06 1.52-4.1% over the window

Growth (CAGR, ttm) · 10Y

Sales: +6.29%2025-06-30 → 2026-06-30189.2B → 201.1B (+6.3% total)+6.67%2023-06-30 → 2026-06-30165.7B → 201.1B (+21.4% total)+9.25%2021-06-30 → 2026-06-30129.2B → 201.1B (+55.6% total)+9.41%2016-06-30 → 2026-06-3081.8B → 201.1B (+145.8% total)
Net income: -7.41%2025-06-30 → 2026-06-305.4B → 5B (-7.4% total)-7.69%2023-06-30 → 2026-06-306.3B → 5B (-21.3% total)+3.24%2021-06-30 → 2026-06-304.2B → 5B (+17.3% total)+7.91%2016-06-30 → 2026-06-302.3B → 5B (+114.0% total)
FCF: +17.85%2025-06-30 → 2026-06-305.3B → 6.3B (+17.8% total)-15.89%2023-06-30 → 2026-06-3010.6B → 6.3B (-40.5% total)+1.71%2021-06-30 → 2026-06-305.8B → 6.3B (+8.8% total)+8.59%2016-06-30 → 2026-06-302.8B → 6.3B (+128.0% total)
Shares: -3.69%2025-06-30 → 2026-06-30225.2M → 216.9M (-3.7% total)-2.73%2023-06-30 → 2026-06-30235.6M → 216.9M (-8.0% total)-2.32%2021-06-30 → 2026-06-30243.8M → 216.9M (-11.1% total)-1.92%2016-06-30 → 2026-06-30263.2M → 216.9M (-17.6% total)

Per-share growth (CAGR, ttm) · 10Y

EPS: -3.92%2025-06-30 → 2026-06-30$23.38 → $22.47 (-3.9% total)-5.07%2023-06-30 → 2026-06-30$26.26 → $22.47 (-14.5% total)+5.71%2021-06-30 → 2026-06-30$17.02 → $22.47 (+32.0% total)+10.02%2016-06-30 → 2026-06-30$8.65 → $22.47 (+159.7% total)
Sales/share: +10.37%2025-06-30 → 2026-06-30$840.29 → $927.35 (+10.4% total)+9.66%2023-06-30 → 2026-06-30$703.22 → $927.35 (+31.9% total)+11.84%2021-06-30 → 2026-06-30$529.98 → $927.35 (+75.0% total)+11.55%2016-06-30 → 2026-06-30$310.97 → $927.35 (+198.2% total)
FCF/share: +22.37%2025-06-30 → 2026-06-30$23.70 → $29.00 (+22.4% total)-13.53%2023-06-30 → 2026-06-30$44.86 → $29.00 (-35.4% total)+4.12%2021-06-30 → 2026-06-30$23.70 → $29.00 (+22.4% total)+10.71%2016-06-30 → 2026-06-30$10.48 → $29.00 (+176.7% total)
Book value/share: +6.59%2025-06-30 → 2026-06-30$194.17 → $206.96 (+6.6% total)+8.48%2023-06-30 → 2026-06-30$162.13 → $206.96 (+27.7% total)+7.61%2021-06-30 → 2026-06-30$143.42 → $206.96 (+44.3% total)+8.44%2016-06-30 → 2026-06-30$92.09 → $206.96 (+124.7% total)
Dividend/share: +2.70%2025-06-30 → 2026-06-30$6.68 → $6.86 (+2.7% total)+7.51%2023-06-30 → 2026-06-30$5.52 → $6.86 (+24.3% total)+10.52%2021-06-30 → 2026-06-30$4.16 → $6.86 (+64.9% total)+10.40%2016-06-30 → 2026-06-30$2.55 → $6.86 (+169.0% total)
Price: +33.00%2025-09-11 → 2026-09-11$314.89 → $418.72 (+33.0% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.-2.32%2023-09-11 → 2026-09-11$449.26 → $418.72 (-6.8% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+3.21%2021-09-10 → 2026-09-11$357.51 → $418.72 (+17.1% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+12.68%2016-09-09 → 2026-09-11$126.89 → $418.72 (+230.0% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.
Total return: +35.06%2025-09-11 → 2026-09-11$310.09 → $418.72 (+35.0% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.-0.82%2023-09-11 → 2026-09-11$429.15 → $418.72 (-2.4% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+4.64%2021-09-10 → 2026-09-11$333.75 → $418.72 (+25.5% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+14.19%2016-09-09 → 2026-09-11$111.04 → $418.72 (+277.1% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.

Fundamentals end at the last reported quarter; price and total return end at the latest close.

Valuation

P/E (ttm)Price ÷ TTM diluted EPS. Net income carries everything below the operating line, including one-off gains. Negative when the trailing year lost money.: 18.6×2016-09 14.462026-09 18.30+26.6% over the window
P/OI (ttm)Price ÷ TTM operating income. Excludes the below-the-line items that make P/E jump — mark-to-market gains, settlements, tax true-ups.: 16.7×2016-09 7.192026-09 16.66+131.6% over the window
Fwd P/E: 13.6×
P/S (ttm)Market cap ÷ TTM revenue.: 0.5×2016-09 0.402026-09 0.45+14.0% over the window
P/B (mrq)Market cap ÷ stockholders' equity at the most recent quarter end.: 2.0×2016-09 1.332026-09 2.02+51.7% over the window
P/FCF (ttm)Market cap ÷ TTM free cash flow (operating cash flow − capex).: 14.4×2016-09 9.732026-09 14.44+48.5% over the window
EV/EBITDA (fy): 16.1×
EV/Sales (ttm): 0.6×
FCF yield (ttm)TTM free cash flow ÷ market cap — the inverse of P/FCF.: 6.93%2016-06 8.4%2026-06 7.4%-11.0% over the window
Dividend yield (fwd)Indicated forward annual dividend ÷ current price — the rate the company has announced, not what was actually paid over the past year.: 1.64%
Dividend/share (fwd): $6.86
Buyback yield (realized, 1y)1 − shares_at(2026-06-30) ÷ shares_at(2025-06-30) = 1 − 216.9M ÷ 225.2M. Point-in-time share counts from the company's own SEC filings (the same count at both ends), published only when the cash flow statement shows repurchases inside that window. A falling price can't inflate it; negative means net dilution.: 3.69%
Shareholder yield (realized, 1y)Buyback leg + dividend leg: shares retired over the year (3.69%) + dividends paid over that year ($1.5B) ÷ market_cap_at(2025-06-30) ($87.6B). Both legs are measured against the start of the window, so a payout can't shrink its own denominator.: 5.41%
Buyback yield (cash, ttm)Buybacks net of issuance over the trailing twelve months ($2.7B) ÷ today's market cap ($90.8B). Dollars SPENT over what the company is worth NOW — a stock that fell after buying reads high.: 2.98%2016-06 0.3%2026-06 3.2%+903.9% over the window
Shareholder yield (cash, ttm)(TTM buybacks net of issuance $2.7B + TTM dividends $1.5B) ÷ today's market cap ($90.8B). Same caveat as the cash buyback yield.: 4.63%2016-06 2.3%2026-06 5.0%+112.5% over the window

Vs own 10Y history

P/E: 70th
P/OI: 97th
P/S: 14th
P/B: 28th
P/FCF: 46th

Bar = where today’s multiple sits in ELV’s own 10-year range:near a decade-low (cheap)→near a decade-high (rich).

Performance · price return · windows as of 2026-09-11

+0.52%

+0.95%

+4.91%

+4.90%

YTD

+20.67%

+38.61%

+17.49%

Financial statements

Open full ELV financials →

Loading financial statements…

Ticker	Name	1M	1D
LLY	Eli Lilly and Company	-8.44%	-0.65%
JNJ	Johnson & Johnson	+2.31%	-0.29%
ABBV	AbbVie Inc.	+3.36%	+0.83%
MRK	Merck & Co. Inc.	+8.28%	-0.54%
UNH	UnitedHealth Group Incorporated Common Stock (DE)	-6.53%	-2.37%
TMO	Thermo Fisher Scientific Inc.	+1.13%	+1.10%
AMGN	Amgen Inc.	-8.80%	-1.34%
GILD	Gilead Sciences Inc.	+5.78%	-0.75%

Elevance Health Inc. (ELV) trades at $418.72 with a live price and an interactive chart covering 24+ years of daily price history, plus key valuation metrics. ChartRow also publishes ELV’s financial statements free — annual and quarterly income statement, balance sheet, and cash flow straight from SEC filings, with P/E and valuation history and dividend data. See full ELV financial statements →

ELV — Elevance Health Inc. price, chart and key statistics